Workflow
Flowserve Acquires Greenray Turbine Solutions, Expanding Aftermarket Capabilities in Industrial Gas Turbines
Businesswire· 2025-12-16 12:30
DALLAS--(BUSINESS WIRE)--Flowserve Corporation (NYSE:FLS) ("Flowserve†or the "Company†), a leading provider of flow control products and services for the global infrastructure markets, announced today that it has acquired U.K.-based Greenray Turbine Solutions, Ltd. ("Greenray†), a comprehensive provider of aftermarket products and services for industrial gas turbines. Through this acquisition, Flowserve gains access to deep product expertise and durable revenue for a large installed base of mission-crit ...
Lahontan Commences Drilling at West Santa Fe
Accessnewswire· 2025-12-16 12:30
TORONTO, ON / ACCESS Newswire / December 16, 2025 / Lahontan Gold Corp. (TSXV:LG)(OTCQB:LGCXF) (the "Company" or "Lahontan") is pleased to announce that it has commenced drilling at its West Santa Fe project, located only 13 km from the Company's Flagship Santa Fe Mine project in Nevada's prolific Walker Lane. A Foremost MPD-1500 track-mounted reverse-circulation drill rig and support equipment has begun Lahontan's maiden drill campaign at West Santa Fe. The initial focus of the West Santa Fe drilling pr ...
Engine Capital Comments on UniFirst Common Shareholders' Decisive Mandate for Change at 2026 Annual Meeting
Businesswire· 2025-12-16 12:30
NEW YORK--(BUSINESS WIRE)--Engine Capital LP (together with its affiliates, "Engine†or "we†), which owns approximately 3.2% of the outstanding shares of common stock of UniFirst Corporation (NYSE: UNF) ("UniFirst†or the "Company†), today commented on the results of the Company's 2026 Annual Meeting (the "Meeting†). Based on the preliminary results of the Meeting, a majority of the common stock outstanding (14,530,548 shares) voted for both of Engine's nominees, Arnaud Ajdler and Michael A. Cr. ...
Envirotech Vehicles Unveils Exclusive AI Infrastructure Expansion Framework With AZIO AI
Globenewswire· 2025-12-16 12:30
Proposed combination positions EVTV at the forefront of sovereign and emerging-market AI infrastructure, spanning data centers, enterprise compute, AI-powered agriculture, and drone-enabled systems, anchored by AZIO AI's $50M+ active pipeline within its first two months of operationHOUSTON and NEWPORT BEACH, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- via IBN -- Envirotech Vehicles, Inc. (NASDAQ:EVTV) ("EVTV" or the "Company") today announced that it has entered into an exclusive strategic acquisition framewo ...
I Think Investors Are Missing The Best Energy Trade For 2026
Seeking Alpha· 2025-12-16 12:30
Core Insights - The year is approaching its end, prompting evaluations of performance in various sectors [1] Group 1: Analyst Focus - Leo Nelissen specializes in analyzing major economic developments related to supply chains, infrastructure, and commodities [2] - The analysis aims to provide actionable investment ideas with a focus on dividend growth opportunities [2] Group 2: Investment Research - iREIT on Alpha offers in-depth research covering REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives [1]
Join AIML's Live Shareholder Update with Chairman & CEO Paul Duffy
Accessnewswire· 2025-12-16 12:30
A Look Back at Key Milestones and Successes Achieved in 2025 What's Ahead: Exciting Plans, Strategic Outlook, and Goals for 2026 Advancing the Next Phase of Commercialization TORONTO, ON / ACCESS Newswire / December 16, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to invite shareholders and stakeholders to join an upcoming Livestream Company Update, hosted by Chairman and CEO Paul Duffy. The livestream event will provide an overview of AIML's key achie ...
Nextech3D.ai Appoints Global Head of Sales
Accessnewswire· 2025-12-16 12:30
Appointment Strengthens Sales Execution as Company Focuses on Scaling Revenue and Efficiency TORONTO, ON / ACCESS Newswire / December 16, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:1SS), an AI-first technology company providing event technology, 3D modeling, and spatial computing solutions, announced today that it has appointed James McGuinness as Global Head of Sales. Mr. McGuinness will lead the Company's sales organization as Nextech focuses on expanding its commercial operations into 2026. ...
Kenorland Minerals Reports Maiden Inferred Resource of 14.5 Mt at 5.47 g/t Au for 2.55 Million Ounces at the Frotet Project, Quebec, Where It Holds a 4% NSR Royalty
TMX Newsfile· 2025-12-16 12:30
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2025) - Kenorland Minerals Ltd. (TSXV: KLD) (OTCQX: KLDCF) (FSE: 3WQ0) ("Kenorland" or the "Company") is pleased to announce a maiden Inferred Mineral Resource of 14.5 Mt at 5.47 g/t for 2.55 million ounces (Moz) of gold for the Regnault gold deposit at the Frotet Project (the "Project") in northern Quebec. Kenorland holds a 4% NSR royalty (the "Frotet Royalty") across the entirety of the Project, which is 100% owned and operated by Sumitomo Metal ...
Seabridge Gold Plans to Spin-Out 11.0 Million Ounce Courageous Lake Gold Project
TMX Newsfile· 2025-12-16 12:30
Toronto, Ontario--(Newsfile Corp. - December 16, 2025) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announces today its intention to spin-out its wholly owned subsidiary, Seabridge Gold (NWT) Inc. (to be renamed "Valor Gold") which owns 100% of the Courageous Lake Gold Project ("Courageous Lake" or the "Project"), located in Canada's Northwest Territories. Following the spin-out, Valor Gold will be focused on advancing the Project through exploration, engineering and permittin ...
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Globenewswire· 2025-12-16 12:30
Core Insights - The FDA has granted Fast Track designation to QTORIN™ rapamycin for the treatment of angiokeratomas, highlighting its potential to address a significant unmet medical need [1][2][3] - Palvella Therapeutics plans to initiate a Phase 2 trial for QTORIN™ rapamycin in the second half of 2026, following discussions with the FDA [1][4] Company Overview - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases without FDA-approved treatments [5] - The company is developing a pipeline of product candidates based on its QTORIN™ platform, with QTORIN™ rapamycin as the lead candidate targeting microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas [5] Industry Context - Angiokeratomas are chronic skin lesions with no FDA-approved therapies, affecting an estimated 50,000 diagnosed patients in the U.S. [1][2] - The FDA's Fast Track program aims to expedite the development and review of drugs for serious conditions, facilitating earlier access for patients [3]